Leukemic residual disease and stem cells in acute myeloid leukaemia and myelodysplasia
Current and Recent Research Grants
1) Awarded 2010 – Collaborative Funding Partner - CIRM (Californian Institute for Regenerative Medicine) / MRC Grant – Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells
This grant is a collaboration between Weissman /Majeti (Stanford University California) / Vyas (Oxford University)/ Burnett (Cardiff University/NCRI AML trials) and myself.
I act as the lead clinician scientist overseeing the immunophenotyping for this study in the UK AML trials.
(£135,000 per year for immunophenotypng over 4 years, UK total grant £2,183882 over 5 years)
2) Awarded 2009 –National Institute for Health Research Programme Grant - Co-investigator, (Lead investigator – Professor David Grimwade, Medical and Molecular Genetics, Guys Hospita, Londonl )
The clinical development and service implementation of molecular screening and minimal residual disease monitoring to direct treatment of acute myeloid leukaemia (£1.997M over 60 months)
3) Awarded 2007 - TRICC (translational research in clinical
trials CRUK/MRC) grant, Lead Investigator.
Evaluation of the prognostic impact and optimal use of immunophenotypic monitoring of residual disease in patients with acute myeloid leukaemia recruited to AML16
(1/4/2007- 31/3/2012 - 5 years £400,000)
4) Joint co- investigator for LRF grant Mark Cobbold (50%) / Dr S Freeman (25%) / Charles Craddock (25%)
Characterising and immunologically targeting the phosphoproteome in acute myeloid leukaemia (2008-2011 – £294,576)
5) Joint principal investigator for LRF grant Prof C. Buckley / Dr S Freeman A role for CD31 (PECAM-1) in regulating Haematopoietic Stem Cell retention in the bone marrow niche (2006-2009 – £156,338)
Paper published A novel role for PECAM-1 (CD31) in regulating haematopoietic progenitor cell compartmentalization between the peripheral blood and bone marrow
6) Freeman SD, Investigation of the potential use of Toll-like receptors and Sialic acid-binding immunoglobulin-like lectins in leukaemia monitoring. UHB Charities; 2004-2007.
Other Collaborations / Studies in Myelodysplasia
1) Development of international strategy / research for the use of immunophenotyping in the diagnosis of myelodysplasia with Professor David Bowen (Leeds – Chairman of NCRN Myelodysplasia Working Party) , Dr Paresh Vyas (Oxford), Ogata (Japan), Della Porta (Italy)
International Flow cytometric MDS Collaborative Study –
Publication in preparation: Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-risk myelodysplastic syndromes: results of a European LeukemiaNET study Matteo G Della Porta*,1 Kiyoyuki Ogata*,2 Cristina Picone,1 Luca Malcovati,1 Cristiana Pascutto,1 Hideto Tamura,2 Hiroshi Handa,3 Magdalena Czader,4 Sylvie Freeman,5 Paresh Vyas,6 Anna Porwit,7 Leonie Saft,7 Theresia M. Westers,8 Canan Alhan,8 Claudia Cali,8 Arjan A. van de Loosdrecht 8 and Mario Cazzola.1
2) Oxford (Vyas) Identificaton CD38 expression on CD34 progenitors as a potential diagnostic tool for myelodysplasia
Paper published by Haematologica -2009